| [1] |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
|
| [2] |
Wang L. Early diagnosis of breast cancer[J]. Sensors (Basel), 2017, 17(7)：1572.
|
| [3] |
Esposito A, Criscitiello C, Locatelli M, et al. Liquid biopsies for solid tumors: understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies[J]. Pharmacol Ther, 2016, 157: 120-124.
|
| [4] |
Duffy MJ, Evoy D, Mcdermott EW. CA 15-3: uses and limitation as a biomarker for breast cancer[J]. Clin Chim Acta, 2010, 411(23/24): 1869-1874.
|
| [5] |
Gorgannezhad L, Umer M, Islam MN, et al. Circulating tumor DNA and liquid biopsy: opportunities, challenges, and recent advances in detection technologies[J]. Lab Chip, 2018, 18(8): 1174-1196.
|
| [6] |
De Mattos-Arruda L, Caldas C. Cell-free circulating tumour DNA as a liquid biopsy in breast cancer[J]. Mol Oncol, 2016, 10(3): 464-474.
|
| [7] |
Saliou A, Bidard FC, Lantz O, et al. Circulating tumor DNA for triple-negative breast cancer diagnosis and treatment decisions[J]. Expert Rev Mol Diagn, 2016, 16(1): 39-50.
|
| [8] |
De Mattos-Arruda L, Cortes J, Santarpia L, et al. Circulating tumour cells and cell-free DNA as tools for managing breast cancer[J]. Nat Rev Clin Oncol, 2013, 10(7): 377-389.
|
| [9] |
Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer[J]. N Engl J Med, 2013, 368(13): 1199-1209.
|
| [10] |
Jen J, Wu L, Sidransky D. An overview on the isolation and analysis of circulating tumor DNA in plasma and serum[J]. Ann N Y Acad Sci, 2000, 906: 8-12.
|
| [11] |
Batth IS, Mitra A, Manier S, et al. Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine[J]. Ann Oncol, 2017, 28(3): 468-477.
|
| [12] |
Schwarzenbach H, Pantel K. Circulating DNA as biomarker in breast cancer[J]. Breast Cancer Res, 2015, 17(1): 136.
|
| [13] |
García-Foncillas J, Alba E, Aranda E, et al. Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review[J]. Ann Oncol, 2017, 28(12): 2943-2949.
|
| [14] |
Zhang YC, Zhou Q, Wu YL. The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer[J]. J Hematol Oncol, 2017, 10(1): 167.
|
| [15] |
Cresswell GD, Nichol D, Spiteri I, et al. Mapping the breast cancer metastatic cascade onto ctDNA using genetic and epigenetic clonal tracking[J]. Nat Commun, 2020, 11(1): 1446.
|
| [16] |
Zhou Y, Xu Y, Gong Y, et al. Clinical factors associated with circulating tumor DNA (ctDNA) in primary breast cancer[J]. Mol Oncol, 2019, 13(5): 1033-1046.
|
| [17] |
U．S. Food and Drug Administration. FDA approves first liquid biopsy next-generation sequencing companion diagnostic test[EB/OL]. [2020-08-07].
URL
|
| [18] |
Khodari W, Sedrati A, Naisse I, et al. Impact of loco-regional treatment on metastatic breast cancer outcome: a review[J]. Crit Rev Oncol Hematol, 2013, 87(1): 69-79.
|
| [19] |
Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA[J]. Cancer Discov, 2014, 4(6): 650-661.
|
| [20] |
Leary RJ, Sausen M, Kinde I, et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing[J]. Sci Transl Med, 2012, 4(162): 162ra154.
|
| [21] |
Beaver JA, Jelovac D, Balukrishna S, et al. Detection of cancer DNA in plasma of patients with early-stage breast cancer[J]. Clin Cancer Res, 2014, 20(10): 2643-2650.
|
| [22] |
Zhang X, Zhao W, Wei W, et al. Parallel analyses of somatic mutations in plasma circulating tumor DNA (ctDNA) and matched tumor tissues in early-stage breast cancer[J]. Clin Cancer Res, 2019, 25(21): 6546-6553.
|
| [23] |
Yoshinami T, Kagara N, Motooka D, et al. Detection of ctDNA with personalized molecular barcode NGS and its clinical significance in patients with early breast cancer[J]. Transl Oncol, 2020, 13(8): 100 787.
|
| [24] |
Olsson E, Winter C, George A, et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease[J]. EMBO Mol Med, 2015, 7(8): 1034-1047.
|
| [25] |
Cavallone L, Aguilar-Mahecha A, Lafleur J, et al. Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer[J]. Sci Rep, 2020, 10(1): 14704.
|
| [26] |
Rothé F, Silva MJ, Venet D, et al. Circulating tumor DNA in HER2-amplified breast cancer: a translational research substudy of the NeoALTTO phase Ⅲ trial[J]. Clin Cancer Res, 2019, 25(12): 3581-3588.
|
| [27] |
Killock D. Personalized MRD assays and therapy?[J]. Nat Rev Clin Oncol, 2019, 16(10): 593.
|
| [28] |
Coakley M, Garcia-Murillas I, Turner NC. Molecular residual disease and adjuvant trial design in solid tumors[J]. Clin Cancer Res, 2019, 25(20): 6026-6034.
|
| [29] |
Garcia-Murillas I, Schiavon G, Weigelt B, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer[J]. Sci Transl Med, 2015, 7(302): 302ra133.
|
| [30] |
Chae YK, Davis AA, Carneiro BA, et al. Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA[J]. Oncotarget, 2016, 7(40): 65 364-65 373.
|
| [31] |
Bosch A, Li Z, Bergamaschi A, et al. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer[J]. Sci Transl Med, 2015, 7(283): 283ra251.
|
| [32] |
Davis AA, Jacob S, Gerratana L, et al. Landscape of circulating tumour DNA in metastatic breast cancer[J]. EBioMedicine, 2020, 58: 102 914.
|
| [33] |
Murtaza M, Dawson SJ, Tsui DW, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA[J]. Nature, 2013, 497(7447): 108-112.
|
| [34] |
Pascual J, Lim JSJ, Macpherson IR, et al. Triplet therapy with palbociclib, taselisib, and fulvestrant in PIK3CA-mutant breast cancer and doublet palbociclib and taselisib in pathway-mutant solid cancers[J]. Cancer Discov, 2021, 11(1): 92-107.
|
| [35] |
Yi Z, Ma F, Rong G, et al. Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China[J]. Cancer Commun (Lond), 2020, 40(6): 260-269.
|
| [36] |
Ma F, Zhu W, Guan Y, et al. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy[J]. Oncotarget, 2016, 7(40): 66 020-66 031.
|
| [37] |
Chu D, Paoletti C, Gersch C, et al. ESR1 mutations in circulating plasma tumor DNA from metastatic breast cancer patients[J]. Clin Cancer Res, 2016, 22(4): 993-999.
|
| [38] |
Turner NC, Swift C, Kilburn L, et al. ESR1 mutations and overall survival on fulvestrant versus exemestane in advanced hormone receptor-positive breast cancer: a combined analysis of the phase Ⅲ SoFEA and EFECT trials[J]. Clin Cancer Res, 2020, 26(19): 5172-5177.
|
| [39] |
Hartmaier RJ, Trabucco SE, Priedigkeit N, et al. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer[J]. Ann Oncol, 2018, 29(4): 872-880.
|
| [40] |
Schiavon G, Hrebien S, Garcia-Murillas I, et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer[J]. Sci Transl Med, 2015, 7(313): 313ra182.
|
| [41] |
Page K, Guttery DS, Fernandez-Garcia D, et al. Next generation sequencing of circulating cell-free DNA for evaluating mutations and gene amplification in metastatic breast cancer[J]. Clin Chem, 2017, 63(2): 532-541.
|
| [42] |
Hanker AB, Brewer MR, Sheehan JH, et al. Correction: an acquired HER2 (T798I) gatekeeper mutation induces resistance to neratinib in a patient with HER2 mutant-driven breast cancer[J]. Cancer Discov, 2019, 9(2): 303.
|
| [43] |
Ma CX, Bose R, Gao F, et al. Neratinib efficacy and circulating tumor DNA detection of HER2 mutations in HER2 nonamplified metastatic breast cancer[J]. Clin Cancer Res, 2017, 23(19): 5687-5695.
|